[go: up one dir, main page]

BR0110871A - Derivados de sulfonamida - Google Patents

Derivados de sulfonamida

Info

Publication number
BR0110871A
BR0110871A BR0110871-9A BR0110871A BR0110871A BR 0110871 A BR0110871 A BR 0110871A BR 0110871 A BR0110871 A BR 0110871A BR 0110871 A BR0110871 A BR 0110871A
Authority
BR
Brazil
Prior art keywords
sulfonamide derivatives
psychiatric
useful
compound
formula
Prior art date
Application number
BR0110871-9A
Other languages
English (en)
Inventor
James Abraham Aikins
Andrew Hendley Fray
William David Miller
Paul Leslie Ornstein
Hamideh Zarrinmayeh
Dennis Michael Zimmerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0110871A publication Critical patent/BR0110871A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"DERIVADOS DE SULFONAMIDA". A presente invenção refere-se a um composto de fórmula (Ia) ou um sal farmaceuticamente aceitável deste que é útil para o tratamento de condições associadas com hipofunção de glutamato, tal como distúrbios psiquiátricos e neurológicos.
BR0110871-9A 2000-05-19 2001-05-04 Derivados de sulfonamida BR0110871A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20582200P 2000-05-19 2000-05-19
PCT/US2001/011746 WO2001090056A1 (en) 2000-05-19 2001-05-04 Sulfonamide derivatives

Publications (1)

Publication Number Publication Date
BR0110871A true BR0110871A (pt) 2003-02-11

Family

ID=22763775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110871-9A BR0110871A (pt) 2000-05-19 2001-05-04 Derivados de sulfonamida

Country Status (25)

Country Link
US (2) US6720357B2 (pt)
EP (1) EP1296944A1 (pt)
JP (1) JP2003534315A (pt)
KR (1) KR20030007643A (pt)
CN (1) CN1429206A (pt)
AR (1) AR028590A1 (pt)
AU (1) AU2001262936A1 (pt)
BR (1) BR0110871A (pt)
CA (1) CA2409829A1 (pt)
CZ (1) CZ20023796A3 (pt)
DZ (1) DZ3344A1 (pt)
EA (1) EA004868B1 (pt)
EC (1) ECSP014079A (pt)
HR (1) HRP20020917A2 (pt)
HU (1) HUP0302291A3 (pt)
IL (1) IL152154A0 (pt)
MX (1) MXPA02010021A (pt)
NO (1) NO20025533L (pt)
NZ (1) NZ521620A (pt)
PE (1) PE20011260A1 (pt)
PL (1) PL358184A1 (pt)
SK (1) SK16322002A3 (pt)
SV (1) SV2002000458A (pt)
WO (1) WO2001090056A1 (pt)
ZA (1) ZA200208746B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
WO2003032974A2 (en) * 2001-10-12 2003-04-24 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
AU2004273865A1 (en) * 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
EP2445883B1 (en) 2009-06-26 2014-08-13 Pfizer Inc. Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
KR101569842B1 (ko) 2009-09-30 2015-11-17 삼성전자 주식회사 텔레비전용 전원공급유닛 및 이를 포함하는 텔레비전
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
CN105579575A (zh) 2013-06-13 2016-05-11 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
JP2002521444A (ja) 1998-07-31 2002-07-16 イーライ・リリー・アンド・カンパニー 複素環スルホンアミド誘導体
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
AU5235599A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company N-substituted sulfonamide derivatives
PE20000943A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de sulfonamida

Also Published As

Publication number Publication date
WO2001090056A1 (en) 2001-11-29
ECSP014079A (es) 2002-02-25
AU2001262936A1 (en) 2001-12-03
MXPA02010021A (es) 2003-02-12
KR20030007643A (ko) 2003-01-23
US20040143020A1 (en) 2004-07-22
NO20025533D0 (no) 2002-11-18
JP2003534315A (ja) 2003-11-18
US6720357B2 (en) 2004-04-13
HRP20020917A2 (en) 2004-02-29
EA200201232A1 (ru) 2003-04-24
HUP0302291A3 (en) 2006-11-28
HUP0302291A2 (hu) 2003-11-28
PE20011260A1 (es) 2001-12-11
AR028590A1 (es) 2003-05-14
IL152154A0 (en) 2003-05-29
CA2409829A1 (en) 2001-11-29
EP1296944A1 (en) 2003-04-02
NZ521620A (en) 2004-08-27
CZ20023796A3 (cs) 2003-04-16
DZ3344A1 (fr) 2001-11-29
PL358184A1 (en) 2004-08-09
SK16322002A3 (sk) 2003-05-02
NO20025533L (no) 2003-01-20
EA004868B1 (ru) 2004-08-26
US20030233015A1 (en) 2003-12-18
SV2002000458A (es) 2002-10-24
CN1429206A (zh) 2003-07-09
ZA200208746B (en) 2004-02-10
US6803484B2 (en) 2004-10-12

Similar Documents

Publication Publication Date Title
BR0311494A (pt) Novos indóis substituìdos
BR0312729A (pt) Novos derivados de indol-3-enxofre
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO950297D0 (no) Prolinamidderivater
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
MY138352A (en) Benzothiazole derivatives
BR0012697A (pt) Inibidores da diferenciação de th2
ATE272617T1 (de) Sulfonamid-derivate
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0113590A (pt) 7-oxo-piridopirimidinas
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
BR0110871A (pt) Derivados de sulfonamida
BR0215067A (pt) Piridoquinoxalinas antivirais
SE0101082D0 (sv) Novel use
BR0110874A (pt) Derivados de sulfonamida
EP1034783A4 (en) AMIDE DERIVATIVES
DE69823240D1 (de) Immunmodulierende arzneimittelzusammenstellung
BR0316751A (pt) Análogos de gabapentina para fibromialgia e outros distúrbios relacionados
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
BR0207307A (pt) Inibidores de glyt-1
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
ES2181387T3 (es) Derivados de azetidinocarboxamida para el tratamiento de trastornos del sistema nervioso central.
BR0200476A (pt) Bifenilsulfonamidas tricìclicas como inibidores de metaloproteinase da matriz
EP1210948A4 (en) DRUGS FOR NERVOUS DISEASES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.